Glioblastoma multiforme is one of the aggressive types of the brain cancers. The typical survival rate of the same is fifteen to seventeen months. A new vaccine has come to increase the survival rate up to seven years. The vaccine is based on stimulating the body’s natural immunity to combat the tumor formation.
The scientific paper makes its way to the Journal of Translation Medicine. The research marks the presence of about three hundred and thirty-one glioblastoma patients for the clinical trial of the new vaccine. The Guardian reports, “All of the patients received the standard care for this type of cancer, which involves surgery followed by both radiotherapy and chemotherapy.” Out of the patients enrolled for the clinical trial, about two hundred and thirty-two patients were regularly administered the experimental vaccine accompanying the traditional treatment procedure. The remaining ninety-nine patients were subjected to placebo. In lieu of this, if any of the enrolled patients experience a regrowth of the tumor during the clinical trial was administered with the experimental vaccine.
The observation of the clinical trial infers that the vaccine administration was safe and sound. The patients administered with the experimental vaccine showed a higher survival rate than those who were not subjected to the experimental vaccine treatment. The patients who received the experimental vaccine treatment survived for more than twenty-three months after the surgery. Following surgery, approximately thirty percent of the individuals survived for an average of forty months while a few of them even survived for about seven years.
The vaccine is known as the DCVax immunotherapy vaccine. The basic mechanism underlying the DCVax immunotherapy vaccine therapy is that it involves mixing of the patient’s immune system cells with the tumor markers. This mixture is then injected back in the form of the vaccine to the patients. This combination accurately targets the tumor of the brain cancer.